NasdaqGM:BCAXBiotechs
Should Bicara’s Wider Q1 Loss and New Institutional Stakes Shift the BCAX Investment Narrative?
Bicara Therapeutics has reported first-quarter 2026 results showing a wider net loss of US$56.21 million, with basic and diluted loss per share from continuing operations at US$0.93, up from US$0.68 a year earlier.
At the same time, institutional investors such as FMR LLC and Red Tree have disclosed mid single-digit percentage stakes, highlighting growing professional interest even as losses increase.
We’ll now examine how this larger quarterly loss, against Bicara’s earlier growth...